Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide for treatment of COVID-19
ChiCTR2100051684Phase 3Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leflunomide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Time for viral nucleic acid to turn negative. Started Dec 2022; status: recruiting.
02
Drugs
leflunomide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100051684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051684.